Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Addex TherapeuticsFRA:APE +19.70% 3-Year EBITDA Growth Rate is 20.40% as of Mar. 2026, which is 29% below its 10-year median of 28.55. The stock has 6 warning signs investors should review. Among 1,130 Biotechnology companies, Addex Therapeutics ranks better than 56.9% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 20.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 40.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 17.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Addex Therapeutics was 64.60% per year. The lowest was -88.90% per year. And the median was 28.55% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Addex Therapeutics 3-Year EBITDA Growth Rate Related Terms
FRA:APE vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Addex Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Addex Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Addex Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Addex Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 20.40% mean?
Addex Therapeutics (FRA:APE) has a 3-Year EBITDA Growth Rate of 20.40% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Addex Therapeutics and its competitors. This is 29% below median its historical median of 28.55. According to the industry distribution chart, Addex Therapeutics ranks #487 out of 1130 companies in the Biotechnology industry, placing it in the top 43.1%.
Is Addex Therapeutics' 3-Year EBITDA Growth Rate too high?
Addex Therapeutics' current 3-Year EBITDA Growth Rate of 20.40% is 29% below median its 10-year median of 28.55. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Addex Therapeutics' value of 20.40% is 37.4% above this industry median. Based on the distribution chart, Addex Therapeutics ranks #487 out of 1130 companies in the Biotechnology industry, which is above the industry midpoint.
How does Addex Therapeutics' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Addex Therapeutics ranks #487 out of 1130 companies for 3-Year EBITDA Growth Rate. This puts Addex Therapeutics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. Addex Therapeutics' value of 20.40% is 37.4% above this benchmark. While the company's 10-year median is 28.55 vs. the industry median of 14.85, Addex Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Addex Therapeutics's current 3-Year EBITDA Growth Rate of 20.40% is 37.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Addex Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Addex Therapeutics's current 3-Year EBITDA Growth Rate is 20.40%, which is 29% below median its own 10-year median of 28.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Addex Therapeutics stock overvalued right now?
Addex Therapeutics (FRA:APE) has a current 3-Year EBITDA Growth Rate of 20.40%. The current 3-Year EBITDA Growth Rate is 20.40%, which is 29% below median its 10-year median of 28.55 and 37.4% above the Biotechnology industry median of 14.85. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Addex Therapeutics (FRA:APE), the current 3-Year EBITDA Growth Rate is 20.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:APE has been successfully added to your 
